[sheet: Summary]

Description	TY 2017	TY 2018	TY 2019	TY 2020	Total
Legacy IP Non-Americas Net Sales	$814,600,000	$762,300,000	$691,800,000	$624,100,000	$2,892,800,000
PPC Royalty Rate	4.5%	4.5%	4.5%	4.5%
Royalty Paid (PPC Position @ 4.5%)	$36,657,000	$34,303,500	$31,131,000	$28,084,500	$130,176,000
IRS Proposed Royalty Rate	11.0%	11.0%	11.0%	11.0%
Royalty at IRS Rate (@ 11.0%)	$89,606,000	$83,853,000	$76,098,000	$68,651,000	$318,208,000
Proposed Royalty Adjustment (Difference)	$52,949,000	$49,549,500	$44,967,000	$40,566,500	$188,032,000
Rate Differential (IRS − PPC)	6.5%	6.5%	6.5%	6.5%
IRS NOPA Rounded Total Proposed Adjustment	$188,040,000
Tax on Proposed Adjustment (21% simplified)	$11,119,290	$10,405,395	$9,443,070	$8,518,965	$39,486,720
IRC § 6662(e) Penalty (20% of tax)	$2,223,858	$2,081,079	$1,888,614	$1,703,793	$7,897,344
Total Potential Exposure (Tax + Penalty)	$13,343,148	$12,486,474	$11,331,684	$10,222,758	$47,384,064

Note: TY 2017 pre-TCJA rate is 35%; see Tax Impact Detail sheet for corrected computation. This summary uses 21% as a simplified rate for illustrative purposes.

[sheet: Net Sales Detail]

Product	Territory	TY 2017 Net Sales	TY 2018 Net Sales	TY 2019 Net Sales	TY 2020 Net Sales	Notes
Compound A (Cardiovascular)	Non-Americas (EMEA + APAC)	$312,400,000	$287,600,000	$254,200,000	$221,800,000	Pre-2012 vintage; generic erosion accelerating
Compound B (Metabolic/Endocrine)	Non-Americas (EMEA + APAC)	$248,700,000	$234,100,000	$218,500,000	$204,300,000	Pre-2012 vintage; slower decline due to limited generics
Compound C (CNS/Neurology)	Non-Americas (EMEA + APAC)	$165,200,000	$156,800,000	$143,600,000	$129,400,000	Pre-2012 vintage; patent expiry EU 2016
Compound D (Anti-Infective/Other)	Non-Americas (EMEA + APAC)	$88,300,000	$83,800,000	$75,500,000	$68,600,000	Pre-2012 vintage; mature lifecycle
Total Legacy IP Non-Americas Net Sales	$814,600,000	$762,300,000	$691,800,000	$624,100,000	Royalty base for intercompany license
Year-over-Year Change ($)	($52,300,000)	($70,500,000)	($67,700,000)	Declining trend consistent with product maturation
Year-over-Year Change (%)	-6.4%	-9.2%	-9.8%
Cumulative 4-Year Total	$2,892,800,000

[sheet: Royalty Comparison]

Tax Year	Non-Americas Legacy Net Sales	PPC Rate	Royalty at PPC Rate	IRS Proposed Rate	Royalty at IRS Rate	Rate Differential	Proposed Adjustment Amount	Adjustment as % of Net Sales
2017	$814,600,000	4.5%	$36,657,000	11.0%	$89,606,000	6.5%	$52,949,000	6.5%
2018	$762,300,000	4.5%	$34,303,500	11.0%	$83,853,000	6.5%	$49,549,500	6.5%
2019	$691,800,000	4.5%	$31,131,000	11.0%	$76,098,000	6.5%	$44,967,000	6.5%
2020	$624,100,000	4.5%	$28,084,500	11.0%	$68,651,000	6.5%	$40,566,500	6.5%
Total	$2,892,800,000	$130,176,000	$318,208,000	$188,032,000

[sheet: CUT Benchmarking Support]

Metric	Value	Notes
Analysis Prepared By	Whitmore Valuation Group LLC (Dr. Helena Vasquez, Managing Director; Dr. Rohan Chakrabarti, Senior Director)	Retained under Kovel arrangement (Ref: 1018-00009-KV, dated June 20, 2022)
Number of Comparable Agreements Identified	14	Pharmaceutical license agreements for IP rights
Interquartile Range (IQR) of Royalty Rates	3.1% – 6.8%	Arm's-length range per Treas. Reg. § 1.482-4
25th Percentile Royalty Rate	3.1%	Lower bound of IQR
Median Royalty Rate	4.4%	PPC's 4.5% rate is within 0.1 pp of median
75th Percentile Royalty Rate	6.8%	Upper bound of IQR
PPC Intercompany Royalty Rate	4.5%	Applied to legacy (pre-2012) compounds licensed to PBI for non-Americas territory
IRS Proposed Royalty Rate	11.0%	Based on IRS's selected CUTs — falls well above the 75th percentile of WVG's comparable set
PPC Rate Position within IQR	Within arm's-length range	4.5% falls between 3.1% (25th percentile) and 6.8% (75th percentile)
IRS Rate Position relative to IQR	Above the 75th percentile	11.0% exceeds the IQR upper bound of 6.8% by 4.2 pp
Applicable Regulatory Standard	Treas. Reg. § 1.482-4; CUT Method	Best method rule under Treas. Reg. § 1.482-1(d)
Applicable Statute	IRC § 482	Allocation of income among commonly controlled entities

[sheet: Sensitivity Analysis]

Hypothetical Royalty Rate	TY 2017 Adjustment	TY 2018 Adjustment	TY 2019 Adjustment	TY 2020 Adjustment	Total Adjustment	Tax Impact at 21%	Penalty at 20%	Total Exposure
4.5% (PPC Position — No Adjustment)	$0	$0	$0	$0	$0	$0	$0	$0
5.0%	$4,073,000	$3,811,500	$3,459,000	$3,120,500	$14,464,000	$3,037,440	$607,488	$3,644,928
5.5%	$8,146,000	$7,623,000	$6,918,000	$6,241,000	$28,928,000	$6,074,880	$1,214,976	$7,289,856
6.0%	$12,219,000	$11,434,500	$10,377,000	$9,361,500	$43,392,000	$9,112,320	$1,822,464	$10,934,784
6.5%	$16,292,000	$15,246,000	$13,836,000	$12,482,000	$57,856,000	$12,149,760	$2,429,952	$14,579,712
7.0%	$20,365,000	$19,057,500	$17,295,000	$15,602,500	$72,320,000	$15,187,200	$3,037,440	$18,224,640
7.5%	$24,438,000	$22,869,000	$20,754,000	$18,723,000	$86,784,000	$18,224,640	$3,644,928	$21,869,568
8.0%	$28,511,000	$26,680,500	$24,213,000	$21,843,500	$101,248,000	$21,262,080	$4,252,416	$25,514,496
9.0%	$36,657,000	$34,303,500	$31,131,000	$28,084,500	$130,176,000	$27,336,960	$5,467,392	$32,804,352
10.0%	$44,803,000	$41,926,500	$38,049,000	$34,325,500	$159,104,000	$33,411,840	$6,682,368	$40,094,208
11.0% (IRS Proposed — Full Adjustment)	$52,949,000	$49,549,500	$44,967,000	$40,566,500	$188,032,000	$39,486,720	$7,897,344	$47,384,064

Note: PPC's penalty protection via contemporaneous documentation (Crestfield & Associates) and reasonable cause defense under IRC § 6662(e)(3)(B) — penalty shown for exposure modeling only.

[sheet: Tax Impact Detail]

Tax Year	Proposed Royalty Adjustment	Applicable Federal Tax Rate	Tax on Adjustment	Estimated Interest	Proposed Penalty — IRC § 6662(e) at 20%	Total Year Exposure
2017	$52,949,000	35%	$18,532,150	Note 1	$3,706,430	$22,238,580
2018	$49,549,500	21%	$10,405,395	Note 1	$2,081,079	$12,486,474
2019	$44,967,000	21%	$9,443,070	Note 1	$1,888,614	$11,331,684
2020	$40,566,500	21%	$8,518,965	Note 1	$1,703,793	$10,222,758
Total	$188,032,000	$46,899,580	See Note 1	$9,379,916	$56,279,496

[sheet: Summary]
Description | TY 2017 | TY 2018 | TY 2019 | TY 2020 | Total
Legacy IP Non-Americas Net Sales | $814,600,000 | $762,300,000 | $691,800,000 | $624,100,000 | $2,892,800,000
PPC Royalty Rate | 4.5% | 4.5% | 4.5% | 4.5%
Royalty Paid (PPC Position @ 4.5%) | $36,657,000 | $34,303,500 | $31,131,000 | $28,084,500 | $130,176,000
IRS Proposed Royalty Rate | 11.0% | 11.0% | 11.0% | 11.0%
Royalty at IRS Rate (@ 11.0%) | $89,606,000 | $83,853,000 | $76,098,000 | $68,651,000 | $318,208,000
Proposed Royalty Adjustment (Difference) | $52,949,000 | $49,549,500 | $44,967,000 | $40,566,500 | $188,032,000
Rate Differential (IRS − PPC) | 6.5% | 6.5% | 6.5% | 6.5%
IRS NOPA Rounded Total Proposed Adjustment | $188,040,000
Tax on Proposed Adjustment (21% simplified) | $11,119,290 | $10,405,395 | $9,443,070 | $8,518,965 | $39,486,720
IRC § 6662(e) Penalty (20% of tax) | $2,223,858 | $2,081,079 | $1,888,614 | $1,703,793 | $7,897,344
Total Potential Exposure (Tax + Penalty) | $13,343,148 | $12,486,474 | $11,331,684 | $10,222,758 | $47,384,064
Note: TY 2017 pre-TCJA rate is 35%; see Tax Impact Detail sheet for corrected computation. This summary uses 21% as a simplified rate for illustrative purposes.
[sheet: Net Sales Detail]
Product | Territory | TY 2017 Net Sales | TY 2018 Net Sales | TY 2019 Net Sales | TY 2020 Net Sales | Notes
Compound A (Cardiovascular) | Non-Americas (EMEA + APAC) | $312,400,000 | $287,600,000 | $254,200,000 | $221,800,000 | Pre-2012 vintage; generic erosion accelerating
Compound B (Metabolic/Endocrine) | Non-Americas (EMEA + APAC) | $248,700,000 | $234,100,000 | $218,500,000 | $204,300,000 | Pre-2012 vintage; slower decline due to limited generics
Compound C (CNS/Neurology) | Non-Americas (EMEA + APAC) | $165,200,000 | $156,800,000 | $143,600,000 | $129,400,000 | Pre-2012 vintage; patent expiry EU 2016
Compound D (Anti-Infective/Other) | Non-Americas (EMEA + APAC) | $88,300,000 | $83,800,000 | $75,500,000 | $68,600,000 | Pre-2012 vintage; mature lifecycle
Total Legacy IP Non-Americas Net Sales | $814,600,000 | $762,300,000 | $691,800,000 | $624,100,000 | Royalty base for intercompany license
Year-over-Year Change ($) | ($52,300,000) | ($70,500,000) | ($67,700,000) | Declining trend consistent with product maturation
Year-over-Year Change (%) | -6.4% | -9.2% | -9.8%
Cumulative 4-Year Total | $2,892,800,000
[sheet: Royalty Comparison]
Tax Year | Non-Americas Legacy Net Sales | PPC Rate | Royalty at PPC Rate | IRS Proposed Rate | Royalty at IRS Rate | Rate Differential | Proposed Adjustment Amount | Adjustment as % of Net Sales
2017 | $814,600,000 | 4.5% | $36,657,000 | 11.0% | $89,606,000 | 6.5% | $52,949,000 | 6.5%
2018 | $762,300,000 | 4.5% | $34,303,500 | 11.0% | $83,853,000 | 6.5% | $49,549,500 | 6.5%
2019 | $691,800,000 | 4.5% | $31,131,000 | 11.0% | $76,098,000 | 6.5% | $44,967,000 | 6.5%
2020 | $624,100,000 | 4.5% | $28,084,500 | 11.0% | $68,651,000 | 6.5% | $40,566,500 | 6.5%
Total | $2,892,800,000 | $130,176,000 | $318,208,000 | $188,032,000
[sheet: CUT Benchmarking Support]
Metric | Value | Notes
Analysis Prepared By | Whitmore Valuation Group LLC (Dr. Helena Vasquez, Managing Director; Dr. Rohan Chakrabarti, Senior Director) | Retained under Kovel arrangement (Ref: 1018-00009-KV, dated June 20, 2022)
Number of Comparable Agreements Identified | 14 | Pharmaceutical license agreements for IP rights
Interquartile Range (IQR) of Royalty Rates | 3.1% – 6.8% | Arm's-length range per Treas. Reg. § 1.482-4
25th Percentile Royalty Rate | 3.1% | Lower bound of IQR
Median Royalty Rate | 4.4% | PPC's 4.5% rate is within 0.1 pp of median
75th Percentile Royalty Rate | 6.8% | Upper bound of IQR
PPC Intercompany Royalty Rate | 4.5% | Applied to legacy (pre-2012) compounds licensed to PBI for non-Americas territory
IRS Proposed Royalty Rate | 11.0% | Based on IRS's selected CUTs — falls well above the 75th percentile of WVG's comparable set
PPC Rate Position within IQR | Within arm's-length range | 4.5% falls between 3.1% (25th percentile) and 6.8% (75th percentile)
IRS Rate Position relative to IQR | Above the 75th percentile | 11.0% exceeds the IQR upper bound of 6.8% by 4.2 pp
Applicable Regulatory Standard | Treas. Reg. § 1.482-4; CUT Method | Best method rule under Treas. Reg. § 1.482-1(d)
Applicable Statute | IRC § 482 | Allocation of income among commonly controlled entities
[sheet: Sensitivity Analysis]
Hypothetical Royalty Rate | TY 2017 Adjustment | TY 2018 Adjustment | TY 2019 Adjustment | TY 2020 Adjustment | Total Adjustment | Tax Impact at 21% | Penalty at 20% | Total Exposure
4.5% (PPC Position — No Adjustment) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0
5.0% | $4,073,000 | $3,811,500 | $3,459,000 | $3,120,500 | $14,464,000 | $3,037,440 | $607,488 | $3,644,928
5.5% | $8,146,000 | $7,623,000 | $6,918,000 | $6,241,000 | $28,928,000 | $6,074,880 | $1,214,976 | $7,289,856
6.0% | $12,219,000 | $11,434,500 | $10,377,000 | $9,361,500 | $43,392,000 | $9,112,320 | $1,822,464 | $10,934,784
6.5% | $16,292,000 | $15,246,000 | $13,836,000 | $12,482,000 | $57,856,000 | $12,149,760 | $2,429,952 | $14,579,712
7.0% | $20,365,000 | $19,057,500 | $17,295,000 | $15,602,500 | $72,320,000 | $15,187,200 | $3,037,440 | $18,224,640
7.5% | $24,438,000 | $22,869,000 | $20,754,000 | $18,723,000 | $86,784,000 | $18,224,640 | $3,644,928 | $21,869,568
8.0% | $28,511,000 | $26,680,500 | $24,213,000 | $21,843,500 | $101,248,000 | $21,262,080 | $4,252,416 | $25,514,496
9.0% | $36,657,000 | $34,303,500 | $31,131,000 | $28,084,500 | $130,176,000 | $27,336,960 | $5,467,392 | $32,804,352
10.0% | $44,803,000 | $41,926,500 | $38,049,000 | $34,325,500 | $159,104,000 | $33,411,840 | $6,682,368 | $40,094,208
11.0% (IRS Proposed — Full Adjustment) | $52,949,000 | $49,549,500 | $44,967,000 | $40,566,500 | $188,032,000 | $39,486,720 | $7,897,344 | $47,384,064
Note: PPC's penalty protection via contemporaneous documentation (Crestfield & Associates) and reasonable cause defense under IRC § 6662(e)(3)(B) — penalty shown for exposure modeling only.
[sheet: Tax Impact Detail]
Tax Year | Proposed Royalty Adjustment | Applicable Federal Tax Rate | Tax on Adjustment | Estimated Interest | Proposed Penalty — IRC § 6662(e) at 20% | Total Year Exposure
2017 | $52,949,000 | 35% | $18,532,150 | Note 1 | $3,706,430 | $22,238,580
2018 | $49,549,500 | 21% | $10,405,395 | Note 1 | $2,081,079 | $12,486,474
2019 | $44,967,000 | 21% | $9,443,070 | Note 1 | $1,888,614 | $11,331,684
2020 | $40,566,500 | 21% | $8,518,965 | Note 1 | $1,703,793 | $10,222,758
Total | $188,032,000 | $46,899,580 | See Note 1 | $9,379,916 | $56,279,496

[sheet: Summary]

Record

Parties

Dates

Amounts